…
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Affymax Inc. is a small publicly traded company in the biopharmaceutical sector; current public disclosures provide limited detail on its active product portfolio or operating strategy. Long-term growth could depend on progression of any development-stage programs, successful licensing or partnerships, and execution of a sustainable financing plan, which may benefit investors if realized.
Major risks include typical biotech development and regulatory failure, high cash burn with likely dilution from future financings, limited liquidity and trading volume as a Pink-listed issuer, and strong competition in drug development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
| Income before tax | -16.58M | -93.44M | -61.37M | -14.07M | -77.94M |
| Net income | -14.42M | -93.41M | -61.37M | -14.07M | -76.53M |
| Selling general administrative | 27.53M | 89.71M | 31.88M | 33.33M | 36.72M |
| Gross profit | 1.37M | 49.41M | 47.72M | 112.52M | 114.90M |
| Ebit | -38.00M | -93.95M | -61.24M | -16.39M | -78.01M |
| Ebitda | -37.27M | -91.96M | -59.05M | -14.17M | -75.89M |
| Depreciation and amortization | 0.72M | 1.99M | 2.18M | 2.21M | 2.12M |
| Operating income | -15.05M | -92.04M | -61.41M | -14.45M | -78.94M |
| Other operating expenses | 39.39M | 186.41M | 109.13M | 126.97M | 193.84M |
| Interest expense | 1.56M | 1.44M | 0.14M | 0.14M | 0.10M |
| Non recurring | 20.48M | 44.96M | 44.96M | - | - |
| Income tax expense | -2.16M | -0.03M | 0.00M | 0.00M | -1.41M |
| Total revenue | 1.37M | 94.37M | 47.72M | 112.52M | 114.90M |
| Total operating expenses | 39.39M | 141.45M | 109.13M | 126.97M | 193.84M |
| Cost of revenue | 11.86M | 44.96M | 75.33M | 93.64M | 191.72M |
| Total other income expense net | 22.98M | -0.03M | 0.01M | 0.24M | 0.17M |
| Net income from continuing ops | -14.42M | -93.41M | -61.37M | -14.07M | - |
| Net income applicable to common shares | -14.42M | -93.41M | -61.37M | -14.07M | - |
| Breakdown | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
| Total assets | 7.44M | 118.22M | 119.00M | 131.39M | 211.51M |
| Other current assets | 0.72M | 3.07M | 0.69M | 0.45M | 10.14M |
| Total liab | 8.87M | 109.94M | 43.00M | 58.84M | 144.60M |
| Total stockholder equity | -1.43M | 8.28M | 76.00M | 72.55M | 66.91M |
| Deferred long term liab | - | - | 5.17M | - | - |
| Other current liab | 8.77M | 83.64M | 18.82M | 28.80M | 104.19M |
| Common stock | 0.04M | 0.04M | 0.04M | 0.03M | 0.02M |
| Retained earnings | -558.14M | -543.71M | -450.30M | -388.93M | -374.86M |
| Other liab | - | 10.86M | 22.70M | 11.22M | 10.88M |
| Other assets | 1.12M | 10.40M | 8.36M | 7.99M | 7.32M |
| Cash | 5.60M | 68.27M | 54.34M | 63.50M | 125.30M |
| Total current liabilities | 8.87M | 99.08M | 19.77M | 47.62M | 133.72M |
| Current deferred revenue | - | 55.37M | - | 18.50M | 71.97M |
| Net debt | -5.60M | -59.42M | -54.34M | -63.50M | -116.10M |
| Short term debt | - | 8.84M | - | - | 9.19M |
| Short long term debt | - | 8.84M | - | - | - |
| Short long term debt total | - | 8.84M | - | - | 9.19M |
| Other stockholder equity | 556.67M | 551.96M | 526.24M | 461.43M | 441.80M |
| Property plant equipment | - | 2.98M | 3.01M | 3.98M | 5.47M |
| Total current assets | 6.32M | 102.51M | 107.62M | 99.54M | 190.74M |
| Long term investments | - | 2.32M | - | 19.88M | - |
| Net tangible assets | -1.43M | 8.28M | 76.00M | 72.55M | - |
| Short term investments | - | 9.72M | 44.16M | 33.58M | 35.29M |
| Net receivables | - | 18.36M | 6.94M | - | 20.00M |
| Inventory | - | 3.09M | - | - | - |
| Accounts payable | 0.10M | 6.59M | 0.94M | 0.32M | 0.46M |
| Accumulated other comprehensive income | - | -0.00M | 0.02M | 0.03M | -0.06M |
| Non currrent assets other | 1.12M | 3.53M | 1.48M | 1.19M | 1.53M |
| Non current assets total | 1.12M | 15.71M | 11.38M | 31.84M | 20.77M |
| Breakdown | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
| Investments | 13.18M | 32.03M | 9.22M | -10.75M | - |
| Change to liabilities | -6.49M | 18.24M | -6.58M | -53.62M | 14.31M |
| Total cashflows from investing activities | 14.40M | 28.00M | 8.00M | -11.48M | 49.19M |
| Net borrowings | -10.00M | 10.00M | 10.00M | -9.19M | - |
| Total cash from financing activities | -9.73M | 23.11M | 54.80M | -1.08M | 132.98M |
| Change to operating activities | -29.88M | -6.96M | -9.52M | -16.07M | - |
| Net income | -14.42M | -93.41M | -61.37M | -14.07M | -76.53M |
| Change in cash | -62.67M | 13.93M | -9.16M | -61.80M | 101.25M |
| Begin period cash flow | 68.27M | 54.34M | 63.50M | 125.30M | 24.05M |
| End period cash flow | 5.60M | 68.27M | 54.34M | 63.50M | 125.30M |
| Total cash from operating activities | -67.34M | -37.18M | -71.97M | -49.23M | -80.93M |
| Depreciation | 0.72M | 1.99M | 2.18M | 2.21M | 2.12M |
| Other cashflows from investing activities | 1.23M | -2.48M | 0.04M | - | - |
| Change to inventory | - | -4.51M | -4.51M | -4.51M | - |
| Change to account receivables | 18.36M | -15.53M | -6.94M | 18.56M | 3.13M |
| Sale purchase of stock | 0.27M | 13.11M | 54.80M | 8.11M | -0.00M |
| Other cashflows from financing activities | 0.27M | 10.00M | 8.00M | -11.48M | 9.19M |
| Change to netincome | -33.48M | 57.10M | 10.23M | 12.31M | - |
| Capital expenditures | 0.00M | 4.06M | 1.26M | 0.73M | 0.72M |
| Change in working capital | -20.16M | -2.85M | -22.87M | -49.55M | -17.68M |
| Stock based compensation | 4.44M | 11.21M | 10.03M | 11.52M | 11.17M |
| Other non cash items | -37.92M | 45.89M | -61.30M | 0.65M | -0.01M |
| Free cash flow | -67.34M | -41.24M | -73.23M | -49.96M | -81.64M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| AFFY Affymax Inc. |
- -% |
0.00 | - | - | 1.43 | 0.56 | -0.17 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark G. Thompson | CFO & Sec. | 1962 |
| Mr. Jonathan M. Couchman | CEO, Pres & Director | 1970 |
| Dr. Tracy J. Dunn Ph.D., J.D. | VP of Intellectual Property & Legal Affairs | 1963 |
| Mr. Mark G. Thompson | CFO & Secretary | 1962 |
| Mr. Jonathan M. Couchman CFA | CEO, President & Director | 1970 |
| Dr. Tracy J. Dunn Ph.D., J.D. | Vice President of Intellectual Property & Legal Affairs | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.